Regenerative medicine

Ashlee Morgan Scholarship for Healthcare Students: Nurturing Passion and Innovation in Healthcare Education

Retrieved on: 
Thursday, February 29, 2024
Interest, Medicine, Knowledge, B cell, Amnion, Science, Regenerative medicine, Patient, Student, Nursing

This scholarship, administered by Ashlee Morgan , a certified tissue banking specialist with over a decade of experience, takes a unique approach to healthcare education.

Key Points: 
  • This scholarship, administered by Ashlee Morgan , a certified tissue banking specialist with over a decade of experience, takes a unique approach to healthcare education.
  • To be eligible for the Ashlee Morgan Scholarship for Healthcare Students, applicants must be current undergraduate or graduate students pursuing a degree in a healthcare-related field.
  • The Ashlee Morgan Scholarship for Healthcare Students represents a commitment to nurturing the future leaders and innovators in healthcare.
  • By recognizing excellence, passion, and innovation, Ashlee Morgan aims to contribute to the evolution of medicine and improve lives.

3 Weird (And Delicious) Ways to Incorporate Gundry MD Polyphenol-Rich Olive Oil in Your Diet

Retrieved on: 
Thursday, February 29, 2024
Olive, Salad, Gundry, Mouth, Coffee, Olive oil, Weight loss, Polyphenol, Taste, Regenerative medicine, Cooking, Food, MD, Ice cream, Medicinal plants

LOS ANGELES, Feb. 29, 2024 /PRNewswire/ -- Olive oil, a staple in the Mediterranean diet, has long been celebrated for its remarkable health benefits. This culinary gem is linked to various advantages for heart health and overall well-being. Also packed with polyphenols, some studies have shown that olive oil can support a healthy heart, circulatory system, and immune function while aiding in weight loss.

Key Points: 
  • For optimal health benefits and an unparalleled taste experience, Dr. Gundry recommends the Gundry MD ™ Polyphenol-Rich Olive Oil .
  • Gundry MD Polyphenol-Rich Olive Oil is a potent olive oil designed to provide unparalleled health benefits and flavor.
  • These unique benefits stem from the extraordinary olive trees that Gundry MD Polyphenol-Rich Olive Oil is crafted with.
  • Gundry MD Polyphenol-Rich Olive Oil can be purchased on the Gundry MD website for $49.95 with a 90-day purchase-price guarantee.

Global Polyglycerol Industry Research Report, 2022-2024 and 2030: Higher Uptake of Processed Foods Propel Growth Opportunities, Growing Importance of Emulsifiers

Retrieved on: 
Tuesday, February 27, 2024
Regenerative medicine, Chemical industry, Growth, Synthesis, Potential

DUBLIN, Feb. 27, 2024 /PRNewswire/ -- The "Polyglycerol - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 27, 2024 /PRNewswire/ -- The "Polyglycerol - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • Growth in the Polyglycerol-3 segment is estimated at 8.3% CAGR for the next 8-year period.
  • The Polyglycerol market is experiencing growth driven by increasing global demand for sustainable and natural ingredients.
  • Competition in the market is evident from the strong, active, niche, or trivial presence of 47 players worldwide in 2023.

Regener-Eyes®: Industry Spotlight with CEO & Founder of Regener-Eyes®

Retrieved on: 
Monday, February 26, 2024
THO, Patient, Eye, Osmotic concentration, DED, Regenerative medicine, Telecanthus, Research, Medical device

TAMPA, Fla., Feb. 26, 2024 /PRNewswire/ -- Dr. Maria Sampalis, host of the Reframing Eye Care podcast, welcomes Dr. C. Randall Harrell, the esteemed CEO & Founder of Regener-Eyes®, for an exclusive industry spotlight.

Key Points: 
  • TAMPA, Fla., Feb. 26, 2024 /PRNewswire/ -- Dr. Maria Sampalis, host of the Reframing Eye Care podcast, welcomes Dr. C. Randall Harrell, the esteemed CEO & Founder of Regener-Eyes®, for an exclusive industry spotlight.
  • In this engaging podcast episode, Dr. Harrell delves into the molecular mechanisms behind tear hyperosmolarity (THO) in dry eye, a pivotal topic recently explored in a groundbreaking white paper.
  • "At Regener-Eyes®, our commitment lies in deciphering the underlying causes of dry eye to provide innovative solutions," remarked Dr. Harrell.
  • Don't miss this illuminating conversation between Dr. Maria Sampalis and Dr. C. Randall Harrell, available now on the Reframing Eye Care podcast.

Global Nanomedicine Market Report 2023-2028: United States Emerges as a Key Player

Retrieved on: 
Monday, February 26, 2024
Therapy, Incidence, Natural language processing, Merck, Regenerative medicine, Laboratory, Infection, Gilead Sciences, Nanostructure, Dendrimer, Chronic condition, Investment, Nanocarriers, Quality of life, Ageing, Growth, Johnson & Johnson, Conditional sentence, Government, World Health Organization, Urbanization, Nanotechnology, Geography, Prevalence, Safety, Nanoparticle, Attention, Administration, GE HealthCare, Liposome, Nanomaterials, Abbott Laboratories, Organization, Medicine, Notifiable disease, Diagnosis, Machine learning, Deep learning, Amgen, Research, Cancer

DUBLIN, Feb. 26, 2024 /PRNewswire/ -- The "Nanomedicine Market - Forecasts from 2023 to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 26, 2024 /PRNewswire/ -- The "Nanomedicine Market - Forecasts from 2023 to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The nanomedicine market size is still developing, with ongoing research and development aimed at increasing nanomedicine products' efficacy, safety, and scalability.
  • Due to significant investments made by research facilities, pharmaceutical companies, and the government, the United States has a sizable nanomedicine market revenue share.
  • Key Players in the Nanomedicine Market:
    Abbott Laboratories: Nanomaterials, diagnostics, and medical equipment are the primary areas of focus at Abbott Laboratories.

Hyperbaric Oxygen Therapy Shows Promise in Addressing Long COVID Pathophysiology, According to Clinical Review Authored by Hyperbaric Medical Solutions Directors

Retrieved on: 
Thursday, February 22, 2024
Regenerative medicine, MD, Quality of life, Safety, Medicine, Pathophysiology, Deficit spending, Fatigue, Patient, COVID, HBOT, Frontiers in Medicine, Research, Pharmaceutical industry

WOODBURY, N.Y., Feb. 22, 2024 /PRNewswire-PRWeb/ -- A groundbreaking clinical review published in Frontiers in Medicine reveals promising findings on the effectiveness of hyperbaric oxygen therapy (HBOT) in addressing the pathophysiology of long COVID. The study, titled "Hyperbaric Oxygen Effectively Addresses the Pathophysiology of Long COVID: Clinical Review," was authored by the National Medical Director, and the New England Clinical Director of Hyperbaric Medical Solutions, alongside three other esteemed researchers.

Key Points: 
  • A groundbreaking clinical review published in Frontiers in Medicine reveals promising findings on the effectiveness of hyperbaric oxygen therapy (HBOT) in addressing the pathophysiology of long COVID.
  • WOODBURY, N.Y., Feb. 22, 2024 /PRNewswire-PRWeb/ -- A groundbreaking clinical review published in Frontiers in Medicine reveals promising findings on the effectiveness of hyperbaric oxygen therapy (HBOT) in addressing the pathophysiology of long COVID.
  • The study, titled "Hyperbaric Oxygen Effectively Addresses the Pathophysiology of Long COVID: Clinical Review," was authored by the National Medical Director, and the New England Clinical Director of Hyperbaric Medical Solutions, alongside three other esteemed researchers.
  • Hyperbaric Medical Solutions , a leading provider of hyperbaric oxygen therapy, has been at the forefront of treating long COVID patients with positive outcomes.

ROSM Celebrates 10 Years of Advancing Patient Care Through Regenerative Medicine

Retrieved on: 
Tuesday, February 20, 2024
Medicine, Regenerative medicine, Sports medicine, Patient, Research, Elective surgery, Medical imaging

WASHINGTON , Feb. 20, 2024 /PRNewswire/ -- Regenerative Orthopedics & Sports Medicine ( ROSM ) is leading the paradigm shift in orthopedics & sports medicine and is thrilled to announce its 10th anniversary as of February 6.

Key Points: 
  • WASHINGTON , Feb. 20, 2024 /PRNewswire/ -- Regenerative Orthopedics & Sports Medicine ( ROSM ) is leading the paradigm shift in orthopedics & sports medicine and is thrilled to announce its 10th anniversary as of February 6.
  • Since its inception in 2014, ROSM has been at the forefront of innovation, offering patient-centered care and utilizing cutting-edge technologies to improve lives.
  • "Over the past decade, we've witnessed firsthand the transformative power of regenerative medicine, and we're committed to continuing our journey to make these life-changing therapies accessible to more people."
  • ROSM is confident that the future of medicine lies in harnessing the body's own healing potential.

CollPlant Issues Letter to Shareholders

Retrieved on: 
Thursday, February 15, 2024
Therapy, United Nations Global Compact, CLGN, Cancer, Ulcerative colitis, Regeneration, Regenerative medicine, Inflammatory Bowel Diseases, Breast augmentation, Polymerization, 3D, Patent, Social, AbbVie, Connective tissue, Drug discovery, ESG, Letter, 3D bioprinting, Epidermis, Breast, Genetic engineering, Safety, UC, Stratasys, Hyaluronic acid, Ecosystem, Patient, Medicine, Environment, Tissue

Our long-term collaboration with AbbVie to develop a paradigm-shifting regenerative dermal and soft tissue filler continues to advance.

Key Points: 
  • Our long-term collaboration with AbbVie to develop a paradigm-shifting regenerative dermal and soft tissue filler continues to advance.
  • In June of last year, we announced the achievement of an important milestone under this collaboration which triggered a $10 million payment from AbbVie to CollPlant.
  • Per CollPlant's agreement with AbbVie, CollPlant has the potential to receive additional milestones and option products payments, as well as receive meaningful royalties on product sales.
  • In the second quarter of 2023, CollPlant hired a dedicated expert to lead our Environment, Social and Governance (ESG) effort.

Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Retrieved on: 
Wednesday, February 14, 2024
Engineering, Regeneration, Regenerative medicine, Inflammation, North Carolina State University, Neovascularization, Infection, South Korea, WBC, Wilson College, Tissue engineering, KSBM, Decellularization, Congress, CELU, Trauma, Tissue, Development, Culture of Korea, LSC, Wound healing

FLORHAM PARK, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced that its abstract “Tri-layer decellularized, dehydrated human amniotic membrane supports proliferation and stemness of limbal stem cells derived from induced pluripotent stem cells” has been accepted as a poster presentation at WBC 2024, the 12th World Biomaterials Congress which will be held on 26-31 May 2024 in Daegu, Republic of Korea, and hosted by the Korean Society for Biomaterials (KSBM). The theme of WBC 2024 is “Convergence in Biomaterials: a vision for the future of healthcare.”

Key Points: 
  • The theme of WBC 2024 is “Convergence in Biomaterials: a vision for the future of healthcare.”
    The study described in the poster presentation investigated Celularity’s tri-layer decellularized, dehydrated human amniotic membrane technology product as a carrier of induced pluripotent stem cell derived-limbal stem cells (iPSC-LSC) which were investigated for the treatment of limbal stem cell deficiency (LSCD).
  • Limbal Stem Cell (LSC) transplant is a recognized method to restore the ocular surface in advanced stem cell deficient corneas.
  • Its Tissue Engineering Lab Team is particularly interested in corneal tissue engineering, focusing primarily on ocular surface regeneration.
  • The off-the-shelf availability of existing commercial tri-layer decellularized, dehydrated human amniotic membrane products, in combination with iPSC-LSCs, may improve patient access to LSCD treatment and the therapeutic management of LSCD.

Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury

Retrieved on: 
Tuesday, February 13, 2024
Research, Neurology, FDA, Clinical Trials, Stem Cells, Biotechnology, Pharmaceutical, Health, Science, Oncology, SCI, Spinal cord, Regenerative medicine, Person, Proposition 71, CIRM, Delivery, Injury, Quality of life, Food, Surgeon, Spine, Safety, Inda, Therapy, Lineage, Patient, Journal, Ventilation, Trial of the century, Pharmaceutical industry

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today the clearance, by the U.S. Food and Drug Administration (FDA), of its Investigational New Drug amendment (INDa) for OPC1 , an investigational allogeneic oligodendrocyte progenitor cell transplant for the treatment of spinal cord injury (SCI).

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today the clearance, by the U.S. Food and Drug Administration (FDA), of its Investigational New Drug amendment (INDa) for OPC1 , an investigational allogeneic oligodendrocyte progenitor cell transplant for the treatment of spinal cord injury (SCI).
  • The clearance of our INDa and the initiation of OPC1 clinical testing under our sponsorship represents a significant milestone for this program, and reflects our commitment to developing modern cell therapy product candidates,” stated Brian M. Culley, Lineage CEO.
  • We believe these improvements can lead to a safer surgical procedure for surgeons and patients.
  • The data from the Phase 1/2a clinical study of OPC1 in subacute cervical SCI is available here and the data from the Phase 1 clinical study of OPC1 in acute thoracic SCI is available here .